|
|
Blood, Vol. 109, Issue 12, 5151-5156, June 15, 2007
A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia
Blood Harousseau et al.
109: 5151
Supplemental materials for: Harousseau et al, Vol 109, Issue 12, 5151-5156
Members of the Farnesyltransferase Inhibition Global Human Trials (F.I.G.H.T.) Acute Myeloid Leukemia Study Group:
Alain Berrebi, Zita Borbenyi, Larry D. Cripe, Raghundharao Digumarti, Herve Dombret, Dan Douer, Lee C. Drinkard, Jan Van Droogenbroeck, Ulrich Duhersen, Peter Emanuel, Helen Enright, Sandor Fekete, Pierre Fenaux, Donald Fleming, James Foran, Arnold Ganser, Stuart Goldberg, Richard F. Greil, Jean Luc Harousseau, Donna Hogge, Jerzy Holowiecki, Francoise Huguet, Richard Van der Jagt, Wieslaw Wiktor Jedrzejczak, Richard S. Kaczmarski, Hagop Kantarjian, Judith E. Karp, Wolfgang Kern, Jeff E. Lancet, Werner Linkesch, Elod Laszlo, Jeff Lipton, Alan List, Bob Löwenberg, Dieter Lutz, Johan Maertens, Peter Maslak, Shaun McCann, Petra Muus, Rory O’Donnell, Gered Jan Ossenkoppele, David L. Porter, Josy Reiffers, Tadeusz Robak, Gerry Robbins, Jacob M. Rowe, Tapan K. Saikia, Lee S. Schartzberg, Steve Schey, Muhammad Shurafa, Chaim Shustik, Andrzej Skotnicki, Richard Stone, John Sweetenham, Martin Tallman, Xavier Thomas, Robert Turner, Peter Valent, Edo Vellenga, Leo F. Verdonck, Pierre W. Wijermans, Francis Witz, Dina Ben Yehuda.
|
|
